Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Fortress Biotech (FBIO) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Fortress Biotech (FBIO) over the last 10 years, with Q3 2025 value amounting to $5.8 million.

  • Fortress Biotech's Cost of Revenue rose 2871.84% to $5.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.2 million, marking a year-over-year increase of 930.18%. This contributed to the annual value of $20.9 million for FY2024, which is 879.74% down from last year.
  • Per Fortress Biotech's latest filing, its Cost of Revenue stood at $5.8 million for Q3 2025, which was up 2871.84% from $4.9 million recorded in Q2 2025.
  • Over the past 5 years, Fortress Biotech's Cost of Revenue peaked at $11.2 million during Q3 2021, and registered a low of $2.2 million during Q4 2023.
  • For the 5-year period, Fortress Biotech's Cost of Revenue averaged around $6.4 million, with its median value being $6.4 million (2023).
  • In the last 5 years, Fortress Biotech's Cost of Revenue skyrocketed by 23048.24% in 2021 and then tumbled by 7087.33% in 2023.
  • Over the past 5 years, Fortress Biotech's Cost of Revenue (Quarter) stood at $9.5 million in 2021, then dropped by 18.97% to $7.7 million in 2022, then tumbled by 70.87% to $2.2 million in 2023, then soared by 108.19% to $4.7 million in 2024, then rose by 22.97% to $5.8 million in 2025.
  • Its Cost of Revenue stands at $5.8 million for Q3 2025, versus $4.9 million for Q2 2025 and $4.8 million for Q1 2025.